Change in dyspnoea score · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in exercise tolerance · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Change in hospital utilisation ‐ not measured · chronic obstructive pulmonary disease (COPD) with depression
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Adverse events (nausea, dizziness) · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
It is very uncertain whether comparison 1: 5HT1A partial agonists changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 3: anticonvulsant levetiracetam changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
It is very uncertain whether comparison 4: antipsychotics changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 4: antipsychotics changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
Comparison 5: benzodiazepines may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).
1 finding from 1 review
Relapse · adults with SAnD
Comparison 5: benzodiazepines showed no clear difference in relapse rate ‐ no. relapsed compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 5: benzodiazepines changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 1: 5HT1A partial agonists changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review